Model Number BA28-100/I16-40 |
Device Problems
Collapse (1099); Material Puncture/Hole (1504); Material Integrity Problem (2978)
|
Patient Problems
Aneurysm (1708); Failure of Implant (1924)
|
Event Date 05/21/2018 |
Event Type
Injury
|
Manufacturer Narrative
|
The device involved in the event will not be returned for evaluation as it remains implanted in the patient.If additional information pertinent to the incident is obtained, a follow-up report will be submitted.
|
|
Event Description
|
On (b)(6) 2014 the patient was implanted with a bifurcated stent graft and a suprarenal extension to treat an abdominal aortic aneurysm.On (b)(6) 2018, endologix was made aware of the bifurcated stent graft appearing to have constrained or collapsed.It was reported that the patient has terminal cancer therefore the physician is undecided on whether to intervene or not.The patient is currently being monitored and there have been no additional patient sequelae reported.
|
|
Manufacturer Narrative
|
The manufacturing lot evaluation confirmed all devices met specifications prior to release.The device was not returned as the device remains implanted therefore no evaluation was completed.At the completion of the clinical assessment, clinical was able to find substantial evidence to support the following reported event of stent cage collapse of the main body and the following additional findings of a type 3b endoleak with sac growth.The complaint is most likely device related due to the use of strata material.A root cause investigation was carried out for all afx complaints having an identified failure mode of a type iiib endoleak.Endologix implemented the following corrective actions with the intent of reducing type iiib endoleak events; upgraded graft material (i.E.Duraply) and updates to the ifu and additional physician training.The change to duraply graft material and the ifu changes were put in place (b)(6) 2014.The type iiib endoleak rate for afx manufactured and implanted before these corrective actions were put in place is trending at 2.5%.Since the corrective actions were implemented, the type iiib endoleak events reported for afx devices has been reduced to <0.2%.Endologix continues to investigate this event and similar events to ensure the highest quality and patient safety.
|
|
Event Description
|
During the investigation of this event a type iiib endoleak of the main body with 12 mm sac growth was discovered.Also it was reported that the patient has refused treatment at this time due to other medical issues (terminal cancer).
|
|
Search Alerts/Recalls
|